Invasc Therapeutics -Developing first-in-class drugs for the cardiometabolic market
Invasc Therapeutics -Developing first-in-class drugs for the cardiometabolic market

Investors

InVasc Therapeutics, Inc. is a privately held company, and early on the Company was financed directly by the founders, their friends and family.

In 2010 the Company completed a closing for $3.15 million in a Series A investment lead by Trois Investissements Industriels Internationaux S. A. from Luxembourg.

InVasc plans a Series A round in

early 2010

 

Investor Relations

Investors

Strategic Partners